AIMS: We performed a network meta-analysis of randomized controlled trials (RCTs) in @entity1 with @entity298 to compare the impact of proprotein convertase subtilisin-kexin type 9 @entity563 protease ( @entity756 ) inhibitors with placebo and @entity3709 on lipid levels and outcomes. METHODS AND RESULTS: MEDLINE/PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched for RCTs assessing @entity756 inhibitors vs. other therapies in @entity1 with @entity298 . Network meta-analysis with both a frequentist approach and a Bayesian framework was performed to directly and indirectly compare @entity756 inhibition on lipid levels with @entity3709 and placebo. Odds ratios with 95% confidence intervals (OR [95% CIs]) were generated with random-effects models to compare outcomes. Our meta-analysis included 17 RCTs with 13 083 @entity1 that were randomized to @entity756 inhibitors (n = 8250), placebo (n = 3957), @entity3709 (n = 846), or @entity756 inhibitors and @entity3709 (n = 30). The mean age was 59    10, 52% were male, 34% had @entity453 , 51% had @entity101 , 19% had @entity6 , baseline LDL of 122    36 mg/dL, total @entity165 of 199    39 mg/dL, and HDL of 51    14 mg/dL. inhibitors significantly reduced LDL @entity165 by 57% relative to placebo (P < 0.001) and 36.1% relative to @entity3709 (P < 0.001). Proprotein convertase subtilisin-kexin type 9 @entity563 protease inhibitors reduced the incidence of all-cause mortality [OR 0.43 (95% CI 0.22-0.82), P = 0.01] but was associated with an increased incidence of neurocognitive adverse events [OR 2.34 (95% CI 1.11-4.93), I(2) = 4%, P = 0.02] when compared with placebo. CONCLUSION: Proprotein convertase subtilisin-kexin type 9 @entity563 protease inhibition significantly improved lipid profiles and reduced the incidence of all-cause mortality compared with placebo but had a higher rate of neurocognitive adverse events. Thus, @entity756 inhibitor therapy may serve as an alternative for @entity1 with statin intolerance and for those who do not respond to other lipid reduction therapy.

The impact of proprotein convertase subtilisin-kexin type 9 @entity563 protease inhibitors on lipid levels and outcomes in XXXX with @entity298 : a network meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity756 :: ('255738', 'Gene') :: ['PCSK9'] @entity3709 :: ('MESH:C108606', 'Chemical') :: ['ezetimibe'] @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity298 :: ('MESH:D010538', 'Disease') :: ['primary hypercholesterolaemia'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity1 :: (9606,Species) :: ['patients']
